Cannabidiol for Obsessive-Compulsive Disorder
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to test if Epidiolex can safely and effectively reduce symptoms in adults with obsessive-compulsive and related disorders by calming the brain and reducing anxiety. Epidiolex is a plant-derived pharmaceutical formulation of highly purified cannabidiol (CBD) that has been previously studied for its potential to be misused.
Will I have to stop taking my current medications?
Yes, you will need to stop taking any other psychotropic medications (drugs that affect your mind, emotions, or behavior) to participate in this trial.
Is cannabidiol (CBD) generally safe for human use?
Cannabidiol (CBD), marketed as Epidiolex, is generally considered safe for human use, but it can cause side effects like sleepiness, diarrhea, and changes in appetite. It may also interact with other medications, so it's important to discuss its use with a healthcare provider, especially if you are taking other drugs.12345
How is the drug Epidiolex unique for treating obsessive-compulsive disorder?
What evidence supports the effectiveness of the drug Epidiolex (CBD) for treating obsessive-compulsive disorder?
Research suggests that cannabidiol (CBD) may help with obsessive-compulsive disorder (OCD) by affecting pathways in the brain related to stress and inflammation. CBD has shown potential benefits in other conditions like anxiety and epilepsy, which indicates it might also be helpful for OCD.511121314
Who Is on the Research Team?
Jon E Grant, MD, JD, MPH
Principal Investigator
University of Chicago
Are You a Good Fit for This Trial?
Adults aged 18-65 with a primary diagnosis of OCD, Hoarding Disorder, Skin Picking Disorder, Trichotillomania, or Tourette Syndrome can join. They must have certain symptom severity scores and be able to consent. Excluded are those on other psychotropic meds, at suicide risk, pregnant or not using contraception, using illegal substances, starting new psychological therapies recently or having cognitive impairments.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive Epidiolex (2.5 mg/kg twice daily for one week followed by 5mg/kg twice daily) for two weeks
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Epidiolex
Epidiolex is already approved in United States, European Union for the following indications:
- Seizures associated with Lennox-Gastaut syndrome
- Seizures associated with Dravet syndrome
- Seizures associated with tuberous sclerosis complex
- Seizures associated with Lennox-Gastaut syndrome
- Seizures associated with Dravet syndrome
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Chicago
Lead Sponsor